The functional derivative can be an Fab-, Fab'-, F(ab)2-, an scFv- or Fv-fragment of the monoclonal antibody or a chimeric antibody.

An important embodiment is one in which the thiolation step produces the Fab' fragment.

The antibody-derived targeting ligand may be a Fab' fragment, a scFv, or the like.

Certolizumab pegol is a PEGylated Fab′ fragment of a humanized anti-TNFα monoclonal antibody.

Preferably, prior to the final mixing step, intrastrand disulfide bonds are formed by oxidation within each Fab' fragment, thereby producing individual Fab' fragments each having a single reactive sulfhydryl group.

Methods of identifying peptidomimetics of these fragments are disclosed.

There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab' fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.

For more than a decade, clinicians have been using a growing number of monoclonal antibodies and related molecules (Fc fusion protein, pegylated Fab).

A method of regulating a preeclamptic/eclamptic patient's sodium/potassium ATPase activity includes the administration of digoxin immune Fab (ovine).

Similarly, a monoclonal antibody directed against the antigenic determinant of interest is enzymatically cleaved to obtain the Fab or F(ab')2 fragment.

The complex can also be made specific for specific cells, by incorporating a targeting moiety such as a Fab' fragment attached to a hydrophilic polymer.

One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody.

Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2.

The invention relates to a crystal complex formed by the extracellulare domain of EGF receptor (EGFR) and the Fab fragment of anti-EGFR antibody matuzumab (EMD 72000).

In another embodiment, the method comprises administering a pharmaceutical composition comprising a biologically effective amount of an anti- CD24 antibody or anti- CD24 Fab fragments to the subject.